Side Effects Persist 16 Years After Prostate Ca Brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

More than half of men receiving high-dose-rate brachytherapy for localized prostate cancer report some side effects that in some cases persist for up to 16 years

ATLANTA—More than half of men receiving high-dose-rate brachytherapy for localized prostate cancer report some side effects that in some cases persist for up to 16 years, according to a retrospective analysis. Sven Henrik Stbinger, MD, of the University Hospital Kiel, Germany, presented the results at the American Urological Association 101st Annual Meeting (abstract 1137).

Surveys were offered to 805 men who were treated with external percutaneous radiation (70 Gy) and dose-escalating high-dose-rate brachytherapy between 1986 and 2002. Men either filled out questionnaires or were interviewed by phone. In survey results from 510 men, the most common short-term side effects included various voiding dysfunctions and diarrhea, including leakage (17%), alguria (14%), diarrhea (13%), and residual urine (12%). Late-onset side effects included proctitis (10%), incontinence (6%), urethral stricture (5%), cystitis (3%), stool incontinence (3%), fistula (1%), and urinary retention (1%).

Of the 299 men who provided information on potency, 33% reported erectile dysfunction that had developed since their treatment. "It is very difficult in a retrospective style to get information from patients before the treatment," Dr. Stbinger said at a press briefing. He noted that these retrospective results do give an idea of what clinicians, researchers, and patients might expect.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content